Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

1-5 of 49 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

The safety, tolerability and effects of taking inhaled PC945 (study drug) for early (‘pre-emptive’) treatment of airway infections by a fungus called Aspergillus will be studied in patients who have received a lung transplant. The amount of study drug that gets into the bloodstream and lungs will also be studied. As the study is open-label, participants will know what treatment they receive. There are two study phases: 1. Surveillance Phase (first 12-weeks post-transplant): participants will receive preventative antifungal treatment, attend hospital visits and have bronchoscopies according to local Standard of Care (SOC). Participants who do not develop a fungal infection will participate in the non-intervention Surveillance Phase only. 2. Treatment Phase (16-weeks including treatment and follow-up): Participants who develop a fungal lung infection will receive either: - Pre-emptive PC945 treatment for 28 days (Pre-Emptive Treatment phase) if diagnosed with an early Aspergillus infection without symptoms/disease, with an optional further 8 weeks of PC945 (Extended Treatment Phase), if required, Or: - 'Non-intervention' group: SOC antifungal treatment and management, if the Aspergillus infection is causing symptoms/disease. Approximately 30 participants will be recruited into the Surveillance Phase from UK sites to identify 10 participants who are eligible for PC945 treatment. All participants will have at least 2 study visits in the Surveillance Phase. Participants in the PC945 Pre-emptive Treatment Phase will have 5 study visits and will be contacted by telephone on up to 3 occasions. Participants in the 8-week Extended Treatment Phase will have 2 additional visits. Study visits and bronchoscopies will be timed to coincide with usual SOC practice where possible; participants may have additional bronchoscopy visits depending on local SOC.

Read more Phase II
  • Trial Reference Number

    113562

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Infective

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.

Phase II
  • Trial Reference Number

    101870

  • Age

    18+

  • Length of participation

    3 weeks

  • Trial status

    Closed to recruitment

  • Therapeutic category

    Mucociliary Clearance

Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Phase III
  • Trial Reference Number

    88959

  • Length of participation

    28 days

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Infective

Remote monitoring & gaming technology for improving outcomes in children with cystic fibrosis

Remote monitoring and gaming technology for improving physiotherapy prescription, adherence and prediction of clinical outcomes in children with cystic fibrosis. Airway clearance, physical activity and exercise can mitigate the progression of CF lung disease, but routine physiotherapy treatments are burdensome and adherence is low. Traditional research has failed to produce credible evidence to guide practice, partly because ‘blinding’ isn’t possible and patient preference can confound results. Following our involvement with the ‘Big Life Fix’ television series https://youtu.be/d6A8R146JWU (BBC2,2016) we have worked with engineers and designers to develop electronically chipped airway clearance devices and wearable activity trackers to facilitate automatic data transmission to clinicians and researchers caring for children with CF. Industry partners (Microsoft) and UCL computer science experts are helping us develop computer games driven by breathing through an airway clearance device (to enhance treatment enjoyment and adherence). The project will use this technology for passive remote capture and transmission of daily longitudinal data during airway clearance, physical activity and exercise to assess impact on clinical outcomes. Innovative big data analysis methods will be used to find out whether: Children with CF should do regular ACTs or exercise, and what the minimum effective dose is physical activity levels have an impact on clinical outcomes airway clearance or exercise is more effective in different children (and how to choose) some airway clearance techniques are better than others airway clearance gaming helps children do treatments more regularly, and whether better adherence improves health alternative to traditional research methods and help identify sensitive composite outcome measures for children with mild signs and symptoms.

Read more
  • Trial Reference Number

    97027

  • Length of participation

    14 months

  • Trial status

    Closed

  • Therapeutic category

    Behavioral

Playphysio

There are many oscillatory PEP devices on the market to use for chest physiotherapy, with strong evidence that they are effective treatments in clearing the lungs. However, they don’t provide the user feedback to confirm that they are using the correct technique or indicate when each blow or treatment session has been completed. As a result this can lead parents to have a lack of confidence in whether their child is completing the physiotherapy session correctly or completely.A father of a CF patient has developed a device alongside the CF team at Cambridge University Hospital called Play Physio, that can be attached to any oscillatory PEP device. The patient can play games which have been designed to encourage the child to comply with the routine and data is collected and sent to the treating clinician in order to monitor compliance. The aims of this study are to look into the safety and efficacy of the Play Physio device and to investigate the effect of the device on compliance. This is a 24 week study in which the CF patients (ages 8-16) use the Play Physio ® device and associated app. Lung function, paper diaries, in app questionnaires and compliance data will all be analysed.

Read more Not Applicable
  • Trial Reference Number

    110395

  • Trial status

    Open to recruitment

  • Therapeutic category

    Other

1-5 of 49 results for all trials